US-based drugmaker Johnson & Johnson (J&J) recently announced that it expects to submit at least 10 new medicines for approval by 2019. The company said that each of the new medicines will have the potential of exceeding nearly $1 billion in revenue.
J&J also announced that it planned more than 40 line extensions of existing and new medicines. The comapny has launched 14 new products since 2009-seven of which already exceed or are on track to achieve sales in excess of $1 billion during 2015.
At its recent meeting with the pharmaceutical analysts, J&J said that it would file for approval of daratumumab for the blood cancer multiple myeloma in the United States and Europe this year, based on mid-stage clinical data. Sirukumab, an antibody for rheumatoid arthritis, and the psoriasis-treating guselkumab, each in the midst of Phase III development are some of other J&J's blockbuster drugs in pipeline.
Apart from these, the company is working on late-stage treatments for depression, respiratory syncytial virus, osteoarthritic pain, influenza, insomnia, hepatitis C and a slew of cancers, comprising a wide pipeline of in-house, in-licensed and acquired assets the company believes can come through in Phase III.
